Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of JNJ-73763989 with nucleos(t)ide analogs and pegylated interferon alfa-2a in chronic hepatitis B
2021-002450-81Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomligisiran, entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide and peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of participants with HBsAg level below 100 IU/mL at Week 24. Started Aug 2021; status: completed.
02
Drugs
tomligisiranentecavirtenofovir disoproxil fumaratetenofovir alafenamidepeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-002450-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002450-81.